Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:

“Advancing CAR-T Therapy for Solid Tumors.

CAR-γδ T cells are emerging as a game-changer in immunotherapy! Unlike classic CAR-αβ T cells, which face challenges with solid tumor penetration and MHC limitations, CAR-γδ T cells recognize antigens independently—making them a powerful option for allogeneic therapy.

In this study, researchers developed CAR-γδ T cells targeting Claudin18.2, showing superior cytotoxicity against solid tumors compared to traditional CAR-αβ T cells. These findings pave the way for a more universal and effective CAR-T strategy in CLDN18.2-positive cancers.

Key Takeaways:

MHC-independent antigen recognition
Enhanced tumor-killing efficiency
Potential for broader allogeneic use.”

“CAR-γδ T Cells Targeting Claudin18.2 Show Superior Cytotoxicity Against Solid Tumor Compared to Traditional CAR-αβ T Cells”

Authors: Yueqi Zhao, Yinghui Li, Shuaiqi Wang, Jingyi Han, Mingyang Lu, Yupeng Xu, Wenhua Qiao, Menghua Cai, Yi Xu, Yu Hu, Jianmin Zhang, Hui Chen, Wei He.

Yan Leyfman: Advancing CAR-T Therapy for Solid Tumors